CA2641308A1 - Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor - Google Patents

Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor Download PDF

Info

Publication number
CA2641308A1
CA2641308A1 CA002641308A CA2641308A CA2641308A1 CA 2641308 A1 CA2641308 A1 CA 2641308A1 CA 002641308 A CA002641308 A CA 002641308A CA 2641308 A CA2641308 A CA 2641308A CA 2641308 A1 CA2641308 A1 CA 2641308A1
Authority
CA
Canada
Prior art keywords
cor
cells
ligand
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002641308A
Other languages
English (en)
Inventor
Zhengping Zhuang
Edward H. Oldfield
Deric M. Park
Irina Lubensky
Jie Li
John S. Kovach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Lixte Biotechnology Holdings Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2641308A1 publication Critical patent/CA2641308A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002641308A 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor Abandoned CA2641308A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77116306P 2006-02-06 2006-02-06
US60/771,163 2006-02-06
US79720106P 2006-05-02 2006-05-02
US60/797,201 2006-05-02
PCT/US2007/003095 WO2007092414A2 (fr) 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Publications (1)

Publication Number Publication Date
CA2641308A1 true CA2641308A1 (fr) 2007-08-16

Family

ID=38345726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002641308A Abandoned CA2641308A1 (fr) 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Country Status (3)

Country Link
EP (1) EP1986619A4 (fr)
CA (1) CA2641308A1 (fr)
WO (1) WO2007092414A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011097712A1 (fr) * 2010-02-11 2011-08-18 The Royal Institution For The Advancement Of Learning/Mcgill University Molécule hybride à la fois agoniste du récepteur de l'acide rétinoïque et inhibitrice de l'histone désacétylase

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097561A1 (fr) * 2007-02-06 2008-08-14 Lixte Biotechology Holdings, Inc. Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
AU2008284364A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
CN101854804B (zh) 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
CA2730428A1 (fr) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Procedes de regulation de la mitose cellulaire par inhibition de la phosphatase de serine/threonine
WO2010147612A1 (fr) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
CA2909160C (fr) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
CN106572989B (zh) 2014-07-24 2021-08-27 H·李·莫菲特癌症中心与研究所公司 用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂
US9833450B2 (en) 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
DK3294287T3 (da) 2015-05-15 2020-06-08 Lixte Biotechnology Inc Oxabicycloheptan-prodrugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
DE10038043B4 (de) * 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AUPR392301A0 (en) * 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011097712A1 (fr) * 2010-02-11 2011-08-18 The Royal Institution For The Advancement Of Learning/Mcgill University Molécule hybride à la fois agoniste du récepteur de l'acide rétinoïque et inhibitrice de l'histone désacétylase

Also Published As

Publication number Publication date
WO2007092414A2 (fr) 2007-08-16
WO2007092414A3 (fr) 2008-05-15
EP1986619A4 (fr) 2010-04-28
WO2007092414A8 (fr) 2008-09-04
EP1986619A2 (fr) 2008-11-05

Similar Documents

Publication Publication Date Title
US20090018142A9 (en) Use of phosphatases to treat tumors overexpressing N-CoR
CA2641308A1 (fr) Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
Burnstock et al. Purinergic signaling in healthy and diseased skin
KR102473113B1 (ko) 암 치료를 위한 병용 요법
Huang et al. Capsaicin protects cortical neurons against ischemia/reperfusion injury via down-regulating NMDA receptors
US20090035292A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
AU2016219853A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
Kyriakou et al. Efficacy of cannabinoids against glioblastoma multiforme: A systematic review
Da Fonseca et al. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review
CN113543773B (zh) 稳定的局部用非诺多泮组合物
US20170136053A1 (en) Novel pharmaceutical composition and uses thereof
US10568873B1 (en) Safranal-sorafenib combination therapy for liver cancer
WO2021144799A1 (fr) Cannabinoïdes destinés à être utilisés dans un traitement
US9867827B1 (en) Methods and formulations for topical treatment of psoriasis
Chen et al. Histone Deacetylase 6 Inhibition Mitigates Renal Fibrosis by Suppressing TGF-β/SMAD3 and eGFR Signaling Pathways: PO0602
Benardeau et al. The Novel Soluble Guanylyl Cyclase (sGC) Activator Runcaciguat Induced Renal Vasodilation and Reduced Kidney Damage in a Rat CKD Model: PO0600
Jiao et al. Crucial Role of STAT6 Signaling in Renal Fibrosis: PO0603
Mori et al. Inhibition of KIM-1-Mediated Fatty Acid Uptake by a Novel Inhibitor Attenuates Pro-Fibrotic Responses in Multiple Models of Human Primary Kidney Epithelial Cells Including Kidney Tubuloids: PO0601
CA3238640A1 (fr) Methode de traitement du cancer par acylfulvene et rayonnement
US20150209364A1 (en) Method for treating epidermoid carcinoma
KR20090047501A (ko) 화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제
WO2011066545A1 (fr) Traitement de l'ostéosarcome humain

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150617